Regeneron Pharmaceuticals, Inc. (REGN) SVP Michael S. Aberman Sells 2,269 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVP Michael S. Aberman sold 2,269 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 0.27% during midday trading on Monday, reaching $515.91. 1,172,490 shares of the company were exchanged. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $521.51. The stock has a market capitalization of $54.47 billion, a price-to-earnings ratio of 62.45 and a beta of 1.53. The company’s 50-day moving average price is $456.19 and its 200 day moving average price is $393.90. Regeneron Pharmaceuticals also saw some unusual options trading activity on Friday. Traders purchased 1,150 put options on the company. This represents an increase of 496% compared to the typical daily volume of 193 put options.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. During the same period in the previous year, the company earned $2.57 earnings per share. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $12.68 earnings per share for the current year.

WARNING: This report was reported by sleekmoney and is the property of of sleekmoney. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-svp-michael-s-aberman-sells-2269-shares-of-stock/1941711.html.

Several equities analysts have issued reports on REGN shares. Piper Jaffray Companies set a $446.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, March 8th. Vetr upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 target price for the company in a research note on Wednesday, March 15th. Oppenheimer Holdings, Inc. began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 16th. They set a “hold” rating for the company. CIBC began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 17th. They set a “market perform” rating for the company. Finally, Canaccord Genuity reiterated a “hold” rating and set a $375.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, March 17th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $446.41.

A number of institutional investors have recently added to or reduced their stakes in the company. Korea Investment CORP boosted its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $140,000. Alpha Windward LLC increased its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the last quarter. Welch & Forbes LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $211,000. Finally, Comerica Securities Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $213,000. 66.90% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-svp-michael-s-aberman-sells-2269-shares-of-stock/1941711.html

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *